The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression
Open accessAbstract
PURPOSE: Smoldering multiple myeloma (SMM) is a precursor condition of multiple myeloma (MM) with a 10% annual risk of progression. Various prognostic models exist for risk stratification; however, those are based on solely clinical metrics. The discovery of genomic alterations that underlie disease progression to MM could improve current risk models. METHODS: We used next-generation sequencing to study 214 patients with SMM. We performed whole-exome sequencing on 166 tumors, including 5 with serial samples, and deep targeted sequencing on 48 tumors. RESULTS: We observed that most of the genetic alterations necessary for progression have already been acquired by the diagnosis of SMM. Particularly, we found that alterations of the mitogen-activated protein kinase pathway ( KRAS and NRAS single nucleotide variants [SNVs]), the DNA repair pathway (deletion 17p, TP53, and ATM SNVs), and MYC (translocations or copy number variations) were all independent risk factors of progression after accounting for clinical risk staging. We validated these findings in an external SMM cohort by showing that patients who have any of these three features have a higher risk of progressing to MM. Moreover, APOBEC associated mutations were enriched in patients who progressed and were associated with a shorter time to progression in our cohort. CONCLUSION: SMM is a genetically mature entity whereby most driver genetic alterations have already occurred, which suggests the existence of a right-skewed model of genetic evolution from monoclonal gammopathy of undetermined significance to MM. We identified and externally validated genomic predictors of progression that could distinguish patients at high risk of progression to MM and, thus, improve on the precision of current clinical models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among these, RAS mutations, MYC translocations, APOBEC mutagenesis, and patterns of genomic complexity are the most commonly reported.8,9,11,69,76-83,84”
From Evolution of Multiple Myeloma from a Genomic Perspective (2026) · cites this paper as [78]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Either the decreased efficacy of the immune system or the selection of more aggressive and fit clones will eventually allow the MGUS/SMM to progress into MM.76,78,79,104”
From Evolution of Multiple Myeloma from a Genomic Perspective (2026) · cites this paper as [78]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Specifically, it is peculiar that these high-risk features are underrepresented among high-risk SMM compared to newly diagnosed MM.9,11,69,76-79”
From Evolution of Multiple Myeloma from a Genomic Perspective (2026) · cites this paper as [78]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationUno, H., Cai, T., Pencina, M. J., D'Agostino, R. B., & Wei, L. J. (2011) · Statistics in Medicine · doi:10.1002/sim.4154 · Cited by 1,535
Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070389 · Cited by 921
A monoclonal gammopathy precedes multiple myeloma in most patients
Weiss, B. M., Abadie, J. M., Verma, P. S., Howard, R. S., & Kuehl, W. M. (2009) · Blood · doi:10.1182/blood-2008-12-195008 · Cited by 568
Dispenzieri, A. A., Kyle, R. A., Katzmann, J. A., Therneau, T. M., Larson, D. R., Benson, J. T., Clark, R. J., Melton, L. J., Gertz, M. A., Kumar, S. K., et al. (2007) · Blood · doi:10.1182/blood-2007-08-108357 · Cited by 432
Self-citationRisk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria
Lakshman, A., Rajkumar, S. V., Buadi, F. K., Binder, M., Gertz, M. A., Lacy, M. Q., Dispenzieri, A. A., Dingli, D., Fonder, A. L., Hayman, S. R., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0077-4 · Cited by 299
Self-citationChromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma
Debes-Marun, C. S., Dewald, G., Bryant, S., Picken, E. B., Santana-Dávila, R., Gonzalez-Paz, N. C., Winkler, J. M., Kyle, R. A., Gertz, M. A., Witzig, T. E., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2402797 · Cited by 227
Genomic patterns of progression in smoldering multiple myeloma
Bolli, N., Maura, F., Minvielle, S., Gloznik, D., Szalat, R., Fullam, A., Martincorena, I., Dawson, K. J., Samur, M. K., Zamora, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05058-y · Cited by 222
Self-citationDhodapkar, M. V., Sexton, R., Waheed, S., Usmani, S., Papanikolaou, X., Nair, B., Petty, N., Shaughnessy, J. D., Hoering, A., Crowley, J., et al. (2014) · Blood · doi:10.1182/blood-2013-07-515239 · Cited by 192
MYC dysregulation in the progression of multiple myeloma
MMRF CoMMpass Network, Misund, K., Keane, N., Stein, C. K., Asmann, Y. W., Day, G., Welsh, S., Van Wier, S. A., Riggs, D. L., Ahmann, G., et al. (2020) · Leukemia · doi:10.1038/s41375-019-0543-4 · Cited by 161
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–183 of 183
Huang, M., Ewadi, A., Servatian, N., Noormohamadi, H., Aminov, Z., Muzammil, K., Esfahani, M. A., Abak, N., & Samarkhazan, H. S. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104916 · Cited by 8
Chojnacka, M., Diamond, B. T., Landgren, O., & Maura, F. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.01.006 · Cited by 8
A tower of babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS
Bravo‐Pérez, C., & Gurnari, C. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.01.004 · Cited by 8
Schmidt, T. M., Gahvari, Z. J., & Callander, N. S. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.03.008 · Cited by 8
Sklavenitis‐Pistofidis, R., Lightbody, E. D., Reidy, M., Tsuji, J., Alberge, J.-B., Aranha, M. P., Heilpern-Mallory, D., Roweth, H. G., Huynh, D., Chong, S. J. F., et al. (2025) · Blood · doi:10.1182/blood.2024025102 · Cited by 8
Self-citationBoyle, E. M., Rosenthal, A., Ghamlouch, H., Wang, Y., Farmer, P., Rutherford, M., Ashby, C., Bauer, M., Johnson, S., Wardell, C. P., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01379-y · Cited by 8
Maclachlan, K. H., Bagratuni, T., Kastritis, E., Ziccheddu, B., Lu, S. X., Yellapantula, V. D., Famulare, C., Argyropoulos, K. V., Derkach, A., Papaemmanuil, E., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008876 · Cited by 7
Self-citationRNA processing mechanisms contribute to genome organization and stability in B cells
Miglierina, E., Ordanoska, D., Noir, S. L., & Laffleur, B. (2024) · Oncogene · doi:10.1038/s41388-024-02952-2 · Cited by 7
Ho, P. J., Moore, E., Wellard, C. J., Quach, H., Blacklock, H. A., Harrison, S. J., MacDonald, E., McQuilten, Z., Wood, E. M., Mollee, P. N., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19624 · Cited by 7
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma
Ghobrial, I. M., Gormley, N. J., Kumar, S. K., Mateos, M., Bergsagel, P. L., Chesi, M., Dhodapkar, M. V., Dispenzieri, A. A., Fonseca, R., Getz, G. A., et al. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0022 · Cited by 7
Self-citationEvaluating early intervention in smoldering myeloma clinical trials: a systematic review
Kakkilaya, A., Trando, A., Cliff, E. R. S., Mian, H. S., Hadidi, S. A., Aziz, M., Goodman, A. M., Jeong, A., Lee‐Smith, W., Kelkar, A. H., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae219 · Cited by 7
Diagnosis, risk stratification and management of smouldering multiple myeloma
Zanwar, S., Kumar, S. K., & Rajkumar, S. V. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01119-0 · Cited by 6
Self-citationBerg, S. R., Dikic, A., Sharma, A., Hagen, L., Vågbø, C. B., Zatula, A., Misund, K., Waage, A., & Slupphaug, G. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05345-x · Cited by 8
GLP and G9a histone methyltransferases as potential therapeutic targets for lymphoid neoplasms
Silva-Carvalho, A. É., Filiú-Braga, L. D. D. C., Bogéa, G. M. R., de Assis, A. J. B., Pittella-Silva, F., & Saldanha‐Araújo, F. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03441-y · Cited by 6
Lind, J., Aksoy, O., Prchal‐Murphy, M., Fan, F., Fulciniti, M., Stoiber, D., Bakiri, L., Wagner, E. F., Zwickl-Traxler, E., Sattler, M., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01117-4 · Cited by 6
Mitochondrial dysfunction and drug targets in multiple myeloma
Cui, Y., Wang, F., & Fang, B. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04672-8 · Cited by 6
Molecular genetic aberrations in the pathogenesis of multiple myeloma
Bong, I. P. N., & Esa, E. (2023) · Asian Biomedicine · doi:10.2478/abm-2023-0056 · Cited by 5
Tausch, E., López, C., Stilgenbauer, S., & Siebert, R. (2024) · Medizinische Genetik · doi:10.1515/medgen-2024-2006 · Cited by 5
Bolli, N., D’Agostino, M., Bagratuni, T., Boccadoro, M., Cavo, M., Driessen, C., Einsele, H., Engelhardt, M. M., Gay, F., Gutierrez, N. C., et al. (2025) · HemaSphere · doi:10.1002/hem3.70216 · Cited by 5
Fernandez, N., Perumal, D., Rahman, A. H., Kim‐Schulze, S., Yesil, J., Auclair, D., Adams, H., Parekh, S. S., Gnjatic, S., & Cho, H. J. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.07.001 · Cited by 5
Progress in the Management of Smoldering Multiple Myeloma
Schmidt, T. M., & Callander, N. S. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00623-7 · Cited by 6
Bergiers, I., Köse, M. C., Skerget, S., Malfait, M., Fourneau, N., Ellis, J.-C., Vanhoof, G., Smets, T., Verbist, B. M. P., Maeyer, D. D., et al. (2025) · PLoS Genetics · doi:10.1371/journal.pgen.1011848 · Cited by 6
Self-citationThe landscape of cytogenetic and molecular genetic methods in diagnostics for hematologic neoplasia
Behrens, Y. L., Pietzsch, S., Antić, Ž., Zhang, Y., & Bergmann, A. K. (2024) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2024.101539 · Cited by 4
How to Identify and Manage High-Risk Smoldering Multiple Myeloma
Mouhieddine, T. H. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01596-5 · Cited by 5
Self-citationEarly Detection of Precursor Diseases of Multiple Myeloma
O’Donnell, E., Borden, B. A., & Ghobrial, I. M. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.03.003 · Cited by 4
Self-citationGenomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings?
Lionetti, M., Vià, M. D., Albano, F., Neri, A., Bolli, N., & Musto, P. (2021) · Cancers · doi:10.3390/cancers13133319 · Cited by 4
Jirabanditsakul, C., Dakeng, S., Kunacheewa, C., U‐pratya, Y., & Owattanapanich, W. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221111228 · Cited by 4
Multi-omics analysis of multiple myeloma patients with differential response to first-line treatment
Zheng, B., Yi, K., Zhang, Y., Pang, T., Zhou, J.-Y., He, J., Lan, H., Xian, H., & Li, R. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01148-4 · Cited by 4
Xin, X., Fan, C., Sheng, R., Li, X. C., Zhu, X., Huang, Y., Seraji, H. R., Urazbaeva, D., Atamuratova, Z., & Ubaydullaevna, A. D. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02050-5 · Cited by 4
Lazzaroni, F., Matera, A., Marella, A., Maeda, A., Castellano, G., Marchetti, A., Fabris, S., Pioggia, S., Silvestris, I., Ronchetti, D., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012409 · Cited by 3
Wang, S.-H., Chen, N.-S., Hsu, Y., Hsu, C., Medeiros, L. J., & Chang, K. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155609 · Cited by 3
Mouhieddine, T. H., Ghobrial, I. M., & Nadeem, O. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101641 · Cited by 3
Self-citationEssential procedures of single-cell RNA sequencing in multiple myeloma and its translational value
Du, J., Gu, X.-R., Yu, X., Cao, Y.-J., & Hou, J. (2023) · Blood Science · doi:10.1097/bs9.0000000000000172 · Cited by 3
How We Manage Smoldering Multiple Myeloma
Romano, A., Cerchione, C., Conticello, C., Martinelli, G., & Raimondo, F. D. (2020) · Hematology Reports · doi:10.4081/hr.2020.8951 · Cited by 4
Holstein, S. A., Bahlis, N. J., Bergsagel, P. L., Bhutani, M., Bolli, N., Brownstein, C. M., Démolis, P., Foureau, D., Gay, F., Ghobrial, I. M., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.05.027 · Cited by 3
Self-citationSmoldering multiple myeloma: biology, clinical manifestations and management
Nsiala, L., Bobin, A., Lévy, A., Gruchet, C., Sabirou, F., Gardeney, H., Cailly, L., Manier, S., Moya, N., Tomowiak, C., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1992615 · Cited by 3
Self-citationMultiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges
Sklavenitis‐Pistofidis, R., Getz, G. A., Ghobrial, I. M., & Papaioannou, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.961421 · Cited by 3
Self-citationMolecular Diagnostics of Plasma Cell Neoplasms
Fitzpatrick, M. J., Murali, M. R., & Nardi, V. (2023) · Surgical pathology clinics · doi:10.1016/j.path.2023.01.005 · Cited by 3
Sergeeva, A., Сурин, В. Л., Чабаева, Ю. А., Крайзман, А. А., Solovev, M. V., Kulikov, S. M., & Менделеева, Л. П. (2024) · Clinical oncohematology · doi:10.21320/2500-2139-2024-17-3-256-265 · Cited by 2
Smoldering multiple myeloma: Integrating biology and risk into management
Patel, R., Hill, E., & Dhodapkar, M. V. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.10.002 · Cited by 2
Hyperdiploid myeloma: The silent majority
Wiedmeier, J. E., & Fonseca, R. (2025) · British Journal of Haematology · doi:10.1111/bjh.20190 · Cited by 2
Updates in Plasma Cell Dyscrasias and Related Monoclonal Immunoglobulin-Mediated Renal Disease
Midha, S., Nadeem, O., & Selamet, U. (2022) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2023.151352 · Cited by 2
Canevarolo, R. R., Sudalagunta, P. R., Meads, M. B., Silva, M., Zhao, X., Magaletti, D. M., Alugubelli, R. R., DeAvila, G., Deavila, D., Persi, E., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-26-1082 · Cited by 1
Risk stratification and early intervention in smoldering multiple myeloma
Sra, M. S., & Kumar, S. K. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2576562 · Cited by 1
Self-citationKikuchi, T. (2025) · International Journal of Hematology · doi:10.1007/s12185-025-04096-9 · Cited by 1
Redefining Cure in Multiple Myeloma: Are We Chasing a Moving Target?
Kitundu, J. H. (2025) · Health Science Reports · doi:10.1002/hsr2.71581 · Cited by 2
To treat or not to treat: a state-of-the-art overview of smoldering multiple myeloma
Garg, A., & Devarakonda, S. S. (2026) · Frontiers in Hematology · doi:10.3389/frhem.2025.1706219 · Cited by 1
Burning questions about smouldering myeloma
DeWeerdt, S. (2020) · Nature · doi:10.1038/d41586-020-03225-0 · Cited by 1
Case 29-2023: A 34-Year-Old Woman with Abdominal Distention and Acute Kidney Injury
Jagannath, S., Anderson, M., Yee, A. J., & Hasserjian, R. P. (2023) · New England Journal of Medicine · doi:10.1056/nejmcpc2027091 · Cited by 1
Yamamoto, M., Shindo, M., Funayama, T., Sumi, C., Saito, T., Toki, Y., Hatayama, M., Ono, Y., Sato, K., Mizukami, Y., et al. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117590 · Cited by 1
Testa, U., Leone, G. G. M., Pelosi, E., Castelli, G., & Stefano, V. D. (2024) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2024.044 · Cited by 1
Morgan, G. J., Boyle, E. M., & Davies, F. E. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000523 · Cited by 1
Kunacheewa, C., & Manasanch, E. E. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1984225 · Cited by 1
What Is Genomic High-Risk Myeloma?
Davies, F. E., & Walker, B. A. (2022) · Hemato · doi:10.3390/hemato3020021 · Cited by 1
Silva, A. S., Canevarolo, R. R., Meads, M. B., Silva, M. J., Sudalagunta, P. R., Avila, G. D., Alugubelli, R. R., Tungesvik, A., Bell, E. T., Burger, K. L., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-125536/v1 · Cited by 1
Zanwar, S., & Rajkumar, S. V. (2025) · Leukemia · doi:10.1038/s41375-025-02701-8 · Cited by 1
Recent Advancements in Hematology: Knowledge, Methods and Dissemination
Fitzgibbon, J., Busca, A., Gloghini, A., López‐Guillermo, A., Orazi, A., Carlo‐Stella, C., Andrès, E., van Breda, E., Busti, F., Garderet, L., et al. (2020) · Hemato · doi:10.3390/bloods1010003
The BELLINI Study and the Dawn of Precision Medicine in Multiple Myeloma
Bustoros, M. W., & Ghobrial, I. M. (2021) · The Hematologist
Self-citationSaldarriaga, M. M., & Rossi, A. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000528
[Progress in clonal evolution of multiple myeloma].
Wang, Y., An, G., & Qiu, L. (2021) · Europe PMC (PubMed Central) · doi:10.3760/cma.j.issn.0253-2727.2021.07.017 · Cited by 1
Oben, B., Cosemans, C., Geerdens, E., Linsen, L., Vanhees, K., Maes, B., Theunissen, K., Cruys, B., Lionetti, M., Arijs, I., et al. (2022) · Cancers · doi:10.3390/cancers14041035 · Cited by 1
Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 1
Fitzgibbon, J., Park, S., Cook, G., Paiva, B., Gloghini, A., van Breda, E., Busti, F., Garderet, L., Dolcetti, R., Robin, M., et al. (2020) · Hemato · doi:10.3390/bloods1010005 · Cited by 1
Yee, A. J., Hideshima, T., Raje, N. S., & Anderson, K. C. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm122.pub2
Self-citationTermini, R., Žihala, D., Terpos, E., Pérez-Montaña, A., Jelı́nek, T., Raab, M. S., Weinhold, N., Mai, E. K., Grab, A. L., Corre, J., et al. (2023) · doi:10.1158/1078-0432.c.6532880
The Age of Immune-therapy in Multiple Myeloma with a Collective Goal for a Cure
Larios, J. M., & Terebelo, H. R. (2023) · Medical Research Archives · doi:10.18103/mra.v11i10.4607
Challenges in designing and running smouldering myeloma interventional clinical trials
Lecat, C. S. Y., Boyle, E. M., Hughes, D., Lee, L. S. H., Smith, D., Bygrave, C., Ramasamy, K., & Yong, K. (2024) · eJHaem · doi:10.1002/jha2.880
Self-citationFor how long has this problem been there?
Bolli, N., & Vià, M. D. (2025) · Blood · doi:10.1182/blood.2024027361
Varga, C., Zimmerman, K. D., Foureau, D., Nazli, S. A., Voorhees, P. M., Atrash, S., Paul, B. A., Ferreri, C. J., Olivier, M., & Bhutani, M. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.06.008
Theprungsirikul, P. P., Wang, R., Ahmad, I., Neparidze, N., Ma, X., Chang, S., & Wang, S. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.06.016
From Silent Clones to Myeloma: Unraveling the Genetic Clues Behind MGUS and Smoldering Myeloma
Larasati, A., Triatmono, V. R., & Ghitha, N. (2025) · Journal La Medihealtico · doi:10.37899/journallamedihealtico.v6i3.2139
Bridging the Gap: Refining Myeloma Precursors and Their Risk of Progression Through Genomics
Saldarriaga, M. M., & Bellman, P. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-02305
Navigating the evolving management of smoldering multiple myeloma
Hammami, M. B., Canevarolo, R. R., Silva, A. S., Alsina, M., Kumar, N. B., Baz, R., & Shain, K. H. (2026) · HemaSphere · doi:10.1002/hem3.70275
Temporal trends in progression risk in smoldering myeloma: a systematic review
Ludwig, H., Kastritis, E., Bernhard, S., van de Donk, N. W. C. J., Boccadoro, M., Terpos, E., Musto, P., Sonneveld, P., & Mohyuddin, G. R. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103750
Self-citationThe genetic architecture of plasma cell disorders
Boyle, E. M. (2020) · theses.fr (ABES) · doi:10.70675/404c872dz0ef2z4f8eza81fz592360ed443b
Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study
Nadeem, O., Aranha, M. P., Redd, R. A., Koontz, M. Z., Matous, J. V., Yee, A. J., Zonder, J. A., Kin, A. D., Magidson, S., Lightbody, E. D., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71483-z
Self-citationSong, C., Chen, T., Yu, S., Huang, T., Chen, T., Wang, C., & Liang, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1793391
McCaul, N., Bingham, R. J., & Blann, A. D. (2026) · British Journal of Biomedical Science · doi:10.3389/bjbs.2025.14745
Bahlis, N. J., Mateos, M. V., & Nooka, A. K. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-517488
Parmar, H. V., Biran, N., Phull, P. M., Doucette, K. R., Palma-Grisi, J. D., Franz, J., Vesole, D. H., & Siegel, D. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1834686
Akhlaghi, T., Nemirovsky, D., Maclachlan, K. H., Firestone, R., Korde, N., Mailankody, S., Lesokhin, A. M., Hassoun, H., Patel, D., Shah, U. A., et al. (2026) · HemaSphere · doi:10.1002/hem3.70473
Smoldering and Early Disease Interception
Puertas, B., Alejo, E., & Mateos, M.-V. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000848
Козич, Ж. М., Климкович, Н. Н., Rudenkova, T. V., Kostyuk, S. A., Kras´ko, O. V., & Пугачева, Ж. Н. (2026) · Medical and Biological Problems of Life Activity · doi:10.58708/2074-2088.2026-3(39)-87-93
Xiong, X., Wang, X., Li, J., & Shen, K. (2026) · Technology in Cancer Research & Treatment · doi:10.1177/15330338261503783
Metadata
- Authors
- Bustoros, M., Sklavenitis-Pistofidis, R., Park, J., Redd, R., Zhitomirsky, B., Dunford, A. J., Salem, K., Tai, Y.-T., Anand, S., Mouhieddine, T. H., Chavda, S. J., Boehner, C., Elagina, L., Neuse, C. J., Cha, J., Rahmat, M., Taylor-Weiner, A., Van Allen, E., Kumar, S., Kastritis, E., Leshchiner, I., Morgan, E. A., Laubach, J., Casneuf, T., Richardson, P., Munshi, N. C., Anderson, K. C., Trippa, L., Aguet, F., Stewart, C., Dimopoulos, M.-A., Yong, K., Bergsagel, P. L., Manier, S., Getz, G., & Ghobrial, I. M.
- Affiliations
- Broad Institute (US)
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
- Dana-Farber Cancer Institute (US)
- Harvard University (US)
- University College London (GB)
- Mayo Clinic (US)
- National and Kapodistrian University of Athens (GR)
- Brigham and Women's Hospital (US)
- Janssen (Belgium) (BE)
- Université de Lille (FR)
- Corresponding author
- Ghobrial, Irene M.
- ORCID
- Bustoros, Mark
- Park, Jihye
- Redd, Robert
- Zhitomirsky, Benny
- Dunford, Andrew J.
- Salem, Karma
- Tai, Yu-Tzu
- Anand, Shankara
- Mouhieddine, Tarek H.
- Chavda, Selina J.
- Boehner, Cody
- Neuse, Carl Jannes
- Cha, Justin
- Rahmat, Mahshid
- Taylor-Weiner, Amaro
- Kumar, Shaji
- Leshchiner, Ignaty
- Morgan, Elizabeth A.
- Laubach, Jacob
- Casneuf, Tineke
- Richardson, Paul
- Munshi, Nikhil C.
- Anderson, Kenneth C.
- Trippa, Lorenzo
- Aguet, François
- Stewart, Chip
- Dimopoulos, Meletios-Athanasios
- Yong, Kwee
- Bergsagel, P. Leif
- Manier, Salomon
- Getz, Gad
- Ghobrial, Irene M.
- Venue
- Journal of Clinical Oncology
- Published
- 2020-07-20
- Volume
- 38
- Issue
- 21
- Pages
- 2380-2389
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC7367550
- OpenAlex
- W3027407129
- Cited by
- 187
- References
- 10
- Citations by year
- 2026: 14 · 2025: 29 · 2024: 35 · 2023: 26 · 2022: 32 · 2021: 35 · 2020: 16
- FWCI
- 17.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Multiple Myeloma Research Foundation
- Leukemia and Lymphoma Society
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Celgene
- European Hematology Association (TRTH177)
- Cancer Research UK
- National Institutes of Health
- Stand Up To Cancer
- Pharmacyclics
- National Human Genome Research Institute (T32HG002295)
- National Cancer Institute (R01CA195688, R01CA205954, R01CA168762, P50CA186781)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- smoldering multiple myeloma, progression to multiple myeloma, KRAS mutation, NRAS mutation, TP53 mutation, ATM mutations, 17p deletion, MYC translocation, MAPK signaling, DNA repair pathways, monoclonal gammopathy of undetermined significance, time to progression
- MeSH terms
- Smoldering Multiple Myeloma, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Risk Factors, Disease Progression, Genomics, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
